AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

Currently, direct oral anticoagulants (DOACs) are the first-line anticoagulant strategy in
patients with non-valvular atrial fibrillation (NVAF). They are characterized by a more …

Apixaban and rivaroxaban are the two most prescribed direct factor Xa inhibitors. With the
increased use of DOACs in real-world settings, safety and efficacy concerns have emerged …

Background Although a growing number of very elderly patients with atrial fibrillation (AF),
multiple conditions, and polypharmacy receive direct oral anticoagulants (DOACs), few …

Background Patients with atrial fibrillation (AF) who are on long-term direct oral
anticoagulants (DOAC) with low anti-Xa or anti-IIa levels may be at higher risk of recurrent …

Importance Although reduced doses of direct oral anticoagulants (DOACs) are approved for
patients with nonvalvular atrial fibrillation (NVAF) at high risk of bleeding, little is known …

Patients with atrial fibrillation (AF) on long-term direct oral anticoagulants (DOACs) may be
at higher risk of bleeding because of higher anti-Xa or anti-IIa levels. However, there is no …

Purpose Older age is associated with inappropriate dose prescription of direct oral
anticoagulants. The aim of our study was to describe the prevalence and the clinical …

Aims Since the introduction of direct oral anticoagulant (DOAC) for atrial fibrillation (AF)
therapy, inappropriate and/or underdosing of these drugs has been a major clinical …

Background: This sub-analysis of the ANAFIE Registry, a prospective, observational study
of> 30,000 Japanese non-valvular atrial fibrillation (NVAF) patients aged≥ 75 years …